# EDGAR Filing Document

**Accession Number:** 0001618835
**File Stem:** 0001493152-26-011613
**Filing Date:** 2026-3
**Character Count:** 12618
**Document Hash:** afc5b63abfc051634aa307b595abcdce
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-011613.hdr.sgml**: 20260319

**ACCESSION NUMBER**: 0001493152-26-011613

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260313

**ITEM INFORMATION**: Termination of a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260319

**DATE AS OF CHANGE**: 20260319

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evofem Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001618835
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 208527075
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36754
- **FILM NUMBER:** 26774221

**BUSINESS ADDRESS:**
- **STREET 1:** 12400 HIGH BLUFF DRIVE
- **STREET 2:** SUITE 600
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** (858) 550-1900

**MAIL ADDRESS:**
- **STREET 1:** 12400 HIGH BLUFF DRIVE
- **STREET 2:** SUITE 600
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Neothetics, Inc.
- **DATE OF NAME CHANGE:** 20140905

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 13, 2026

**EVOFEM BIOSCIENCES, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36754** | **20-8527075** |
| (State or other jurisdiction | (Commission | (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |

---

**7770 Regents Road, Suite 113-618**

**San Diego, California 92122**

(Address of principal executive offices)

**(858) 550-1900**

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of exchange on which registered |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.02. Termination of Material Definitive Agreement.**

As previously disclosed in Current Reports on Form 8-K dated March 26, 2025 and April 3, 2025, on March 20, 2025, Evofem Biosciences, Inc. (the "Company") entered into a License and Supply Agreement with Windtree Therapeutics, Inc. ("Windtree"), which was amended on March 28, 2025 (as amended, the "Agreement"), pursuant to which Windtree agreed to become a manufacturer and supplier of PHEXXI® (lactic acid, citric acid, and potassium bitartrate).

On March 13, 2026, the Company and Windtree entered into a Termination Agreement (the "Termination Agreement") pursuant to which the parties mutually consented to the termination of the Agreement, effective as of such date. There is no termination or any other fees payable in connection with the termination of the Agreement. Certain customary provisions of the Agreement that by their terms survive termination remain in effect.

The foregoing summary of the Termination Agreement does not purport to be complete and is qualified in its entirety by reference to the Termination Agreement, a copy of which is filed as Exhibit 10.1, to this Current Report on Form 8-K, and is incorporated by reference herein.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Termination Agreement by and between the Company and Windtree Therapeutics, Inc. dated March 13, 2026](ex10-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **EVOFEM BIOSCIENCES, INC.** | **EVOFEM BIOSCIENCES, INC.** |
| Dated: March 19, 2026 | By: | */s/ Saundra Pelletier* |
|  |  | Saundra Pelletier |
|  |  | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**<u>TERMINATION AGREEMENT</u>**

This TERMINATION AGREEMENT (this "**Agreement**") is entered into as of March 13, 2026, ("**Effective Date**") by and between Evofem Biosciences, Inc., a Delaware corporation having its principal place of business at 12636 High Bluff Drive, Suite 400, San Diego, CA 92130 (the "**Buyer**"), and Windtree Therapeutics, Inc. a Delaware Corporation having its principal place of business at 2600 Kelly Road, Suite 100, Warrington, PA 18976 ("**Supplier**" and, together with Buyer, the "**Parties**," and each, a "**Party**"). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in that certain License and Supply Agreement, dated as of March 20, 2025 as amended by Amendment No. 1 to License and Supply Agreement also dated as of March 20, 2025 (collectively, the "**License & Supply Agreement**") , by and among the Parties.

WHEREAS, Buyer and Supplier are parties to that certain License & Supply Agreement pursuant to which Supplier was to license certain of Buyer's Intellectual Property in order to have manufactured and to supply to Buyer Buyer's Phexxi Product;

WHEREAS, Supplier needed to establish manufacturing capabilities in order to produce the Products for Buyer and was to issue a Commencement Notice to Buyer once such manufacturing capabilities were established;

WHEREAS, Supplier still has not established the manufacturing capabilities required to manufacture the Products in accordance with the terms of the License and Supply Agreement and the Parties have mutually agreed to terminate the License and Supply Agreement; and

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

AGREEMENT

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. **<u>Termination</u>**. Effective as of the Effective Date hereto, the License and Supply Agreement is hereby terminated without any further action required by either Party, and except as set forth herein, all rights, obligations, and liabilities of the Parties under the License and Supply Agreement shall cease and be cancelled in their entirety, and the License and Supply Agreement shall be null and void and of no further force or effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. **<u>Fees</u>**. There are no fees due to either Party associated with License and Supply Agreement or the termination thereof as set out in this Agreement. Each Party hereto shall bear its own costs and fees incurred in connection with the negotiation and execution of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. **<u>Obligations upon Termination</u>.** In accordance with Section 11.5 of the License and Supply Agreement, Supplier shall immediately cease using any Buyer Specifications, Buyer Assets, Buyer Confidential Information and Buyer Intellectual Property and shall immediately return to Buyer all Buyer Confidential Information, Buyer Assets and any other property belonging to Buyer that is in Supplier's possession.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. **<u>Survival</u>**. The rights and obligations of any sections listed in Section 11.6 of the License and Supply Agreement listed as surviving the termination of the License and Supply Agreement shall survive the termination thereof and remain in full force and effect in accordance with their terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. **<u>Waiver</u>**. Each of Buyer and Supplier hereby waives any all termination conditions and requirements any and all notice requirements or other requirements contained in the License and Supply Agreement that may be deemed to restrict or limit the right of either Party to terminate the License and Supply Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. **<u>Severability</u>**. If any provision of this Agreement is held to be invalid, illegal, or unenforceable under applicable law, such provision shall be modified to the minimum extent necessary to make it valid and enforceable, and the remaining provisions shall remain in full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. **<u>Legal Counsel</u>**. Each Party acknowledges that it has had the opportunity to consult with legal counsel of its choice regarding this Agreement and has either done so or voluntarily chosen not to do so.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. **<u>Governing Law</u>**. This Agreement shall be governed by and construed exclusively in accordance with the laws of the State of Delaware, without giving effect to any choice or conflict of law provision or rule. The Parties hereby irrevocably and unconditionally consent to submit to the sole and exclusive jurisdiction of the federal and state courts located in the State of Delaware for any actions, suits or proceedings arising out of or relating to this Agreement or the transactions contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. **<u>Publicity</u>**. Except as is necessary for governmental notification purposes or to comply with applicable Law or to enforce their respective rights under this Agreement, and except as otherwise agreed to by the Parties hereto in writing, the Parties shall (a) keep the terms of this Agreement confidential and

(b) agree upon the text and the exact timing of any public announcement relating to the transactions contemplated by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. **<u>Entire Agreement</u>**. This Agreement constitutes the entire agreement and understanding of the Parties in respect of the subject matter hereof and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether oral or written, relating to the subject matter hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. **<u>Counterparts</u>**. This Agreement may be executed in any number of counterparts (including by PDF or other electronic transmission, and via Docusign, Adobe Sign, or other similar platforms), each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Electronic signatures shall be deemed to have the same legal effect as original signatures.

[*Signature Page Follows*]

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first written above.

---

| | |
|:---|:---|
| **Evofem Biosciences, Inc.** | **Evofem Biosciences, Inc.** |
| By: | */s/ Saundra Pelletier* |
| Date: | March 13, 2026 |
| Name: | Saundra Pelletier |
| Title: | Chief Executive Officer |
| **Windtree Therapeutics, Inc.** | **Windtree Therapeutics, Inc.** |
| By: | */s/ Jed Latkin* |
| Date: | 3/16/2026 |
| Name: | Jed Latkin |
| Title: | Chief Executive Officer |

---